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Abstract 
Cytokeratins are group of intermediate filament proteins and based on the 
tissue expression, cytokeratins are classified into simple epithelial cytokeratin and 
stratified epithelial cytokeratins. CK expression pattern in the malignant cells are 
usually retained from the cell of origin, and therefore CK are being used in tumor 
typing. Cyfra 21-1 is a soluble fragment of cytokeratin 19 is an acid type cytokeratin, 
with a molecular weight of 40,000d. The assumption is that Cyfra 21-1 is released into 
the bloodstream during cell death, and therefore its level correlates very well with the 
tumour mass, or more specifically with the necrosis in the tumour, which is a function 
of the tumour mass. The aim of this article is to review on cyfra 21-1 and its role as a 
diagnostic and prognostic marker.
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Introduction: specific  and  differentiation  dependent.  The 
epithelial  CK  are  closely  related-both  Amongst the three cytoskeletal systems 
biochemically and immunologically. At present,  found  in  eukaryotic  cells,  the  intermediate 
more than 60 CK genes have been identified  filament (IF) protein family is most complex. 
from the human genome sequence; of them 54  Depending on their polymerization properties 
are functional genes. CK are sub-grouped into  and tissue specificity they are divided into six 
type I (40- 56.5 kDa) and type II (53-67 kDa) CK.  subtypes. Intermediate filaments of type I and 
1
1 Type I are acidic while Type II are basic CK . type II are cytokeratins. Cytokeratins are also 
classified  based  on  the  expression  as  simple  Depending on their tissue expression 
epithelial  cytokeratin  and  sratified  squamous  pattern, they have been grouped into simple 
cytokeratin. CK like all other IF demonstrate  epithelia specific CK (CK7, 8, 18, 19, 20) and 
high resistance to detergent action and to high  stratified epithelia specific CK (CK 4, 5, 13, 14, 
2 etc.). The most abundant epithelial CK are CK  and low ionic salt concentrations. Cytokeratins 
8, 18, 19. Protein structures of CK consist of a  are mainly involved in the protection of epithelial 
central alpha helical rod domain, flanked on  cells  from  mechanical  and  non-mechanical 
either side by amino terminal (head) domain  stresses  that  resulting  in  cell  death.  Other 
and carboxy terminal (tail) domain the alpha  emerging functions include roles in cell signaling, 
helical rod domain is a highly conserved region  the stress response, apoptosis, and other tissue 
amongst  all  IF,  while  the  head  and  the  tail  specific functions.
domains impart differential characteristics like  Cytokeratins
molecular  weights,  isoelectric  point,  and 
2 CK make up the largest subgroup of IF  antigenicity .  The  type  I  keratin  K19  is  the 
proteins  and  represent  the  most  abundant  smallest  keratin  and  is  exceptional  since  it 
proteins in epithelial cells. Their expression is site   369 Cyfra 21-1: An Overview
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Fig 1: protein structure of  cytokeratin intermediate 
filament
fragments 21-1(Cyfra 21-1). Assays for TPA 
measure CK 8, 18, and 19 and assays for TPS 
and Cyfra 21-1 are more specific and measure 
7 CK 18 and CK 19 levels, respectively.
Cyfra 21-1
Cyfra 21-1 is a soluble fragments of 
cytokeratin 19 is an acid type cytokeratin, with 
1 a molecular weight of 40,000d.This marker is 
recognized  by  two  monoclonal  antibodies 
against fragments of CK 19 in the serum. The 
epitopes  of  the  two  antibodies  were 
 The primary function of CK is to  determined to be within helix 2B of the rod 
protect epithelial cell from mechanical and  domain of CK 19, the epitope sequences lie 
non-mechanical stresses that resulting in cell  within  the  a.a  sequence  311-335  for  the 
death. Other emerging functions include roles  catcher antibody Ks 19.1 and within 346-367 
in  cell  signaling,  the  stress  response,  for the detector BM 19.21. These sequences 
apoptosis, and other tissue specific functions.  are  unique  as  could  be  confirmed  from 
The  involvement  of  CK  in  a  number  of  sequence  database.  Both  these  antibodies 
4 raised by immunization of mice with MCF-7  human  diseases  is  now  established . 
cells. Cytokeratins undergo several post-translational 
modifications  these  modifications  influence  The  cytokeratins  appear  to  be 
the  biological  activity  of  the  filaments  distributed in the various epithelia, according 
resulting in increased solubility and filament  to  the  cell  differentiation.  During  the 
2. reorganization malignant transformation, the epithelial cells 
appear to contain the same cytokeratins as do  CK  expression  pattern  in  the 
normal cells. malignant cells is usually retained from the cell 
of origin, and therefore CK are being used in  In vitro cleavage of CK19 protein has 
5 tumor typing .Simple epithelia specific CK 8,  been  reported  by  to  occur  through 
18 and 19 are normally not expressed in oral  spontaneous caspase 3 activity, resulting in the 
tissues, however, they are expressed in oral  release of Cyfra 21-1 into the supernatants of 
SCC. Aberrant expression of CK 8 and 18 is  cancer cell lines. The elevation of extracellular 
the  most  common  change  in  human  oral  Cyfra  21-1  concomitantly  with  significant 
cancer.Ck 8 and 18 expression has also been  increase  of  intracellular  Cyfra  21-1  during 
correlated  with  invasiveness  of  the  tumor  apoptosis;  furthermore,  the  cell  dying  by 
margin and poor prognosis of human oral  caspase independent death in the presence of 
6 SCC . the Z-VAD caspase inhibitor did not release 
measurable  Cyfra  21-1.  So,  the  release  of  Cytokeratin  deposition  has  been 
Cyfra 21-1 has been suggested to occur in cells  reported  to  occur  in  the  necrotic  regions 
during intermediate stage of apoptosis, as a  intratumorally  because  of  increased 
consequence of caspase activation, then into  proteolytic  activity  in  these  cells.  Another 
the extracellular space. Apoptosis results in  consequence  of  the  increased  proteolytic 
fragmentation of cells into apoptotic bodies  activity in tumor cells is the appearance CK 
2 which are engulfed by neighboring cells and  fragments in the sera of cancer patients . The 
macrophages. Apoptotic bodies that are not  three  most  frequently  used  CK  which  are 
engulfed  by  macrophages  will  disintegrate  being evaluated as serum markers for their 
('secondary necrosis') and their contents may  utility  in  clinical  applications  are  tissue 
8 subsequently reach the circulation . polypeptide antigen (TPA), tissue polypeptide 
specific  antigen  (TPS),  and  cytokeratin 
widely  lacks  the  non-á-helical  tail  domain 
typical for all other keratins. So it is also called as 
3 tail-less intermediate filament protein .  370 Cyfra 21-1: An Overview
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Fig 2: schematic diagram shows cytokeratin 
fragments in circulation
13  Yen  et  al  (1998) assessed  clinical 
value  of  CYFRA  for  squamous  cell 
carcinoma of the head and neck, and found 
diagnostic  sensitivity  of  CYFRA  was 
superior  especially  for  nasopharyngeal 
carcinoma.  So  CYFRA  may  be  useful  in 
monitoring recurrence of certain types of 
SCCHN, which are sometimes difficult to 
detect.
7 Nagler  et  al  (1999) examined  the 
early  diagnoses  and  treatment  monitoring 
roles  of  cyfra  21-1  and  found  to  be  Cyfra 21-1, as reported before, is a 
significant. soluble  fragment  of  cytokeratin  19.  The 
14  assumption is that Cyfra 21-1 is released into  Deng et al (2003) in his study found 
the  bloodstream  during  cell  death,  and  that Serum levels of CYFRA 21-1 in patients 
therefore its level correlates very well with the  with HNSCC were significantly higher than 
tumour  mass,  or  more  specifically  with  the  those  of  healthy  controls  and  concluded 
necrosis in the tumour, which is a function of  CYFRA  21-1  is  valuable  not  only  for 
the tumour mass. The finding that Cyfra 21-1  diagnosis but also for close monitoring of 
levels may be an independent marker and the  patients with HNSCC.
preferred prognostic factor in head and neck  15 Zhong et al (2007) also found there  cancer may indicate that this marker reflects  was significant correlation  in  cyfra level with  tumour mass more accurately than it does the  tumour  recurrence  and  survival  rate,  the  stage  of  the  disease  as  expressed  by  the  higher the serum Cyfra 21-1; the higher the  TNM.  This  findings  may  also  have  a  tumour recurrence rate and lower the survival  therapeutic implication, as the tumour mass  rate. So he concluded serum Cyfra 21-1 was an  is one of the main parameters in deciding a  independent prognostic factor for OSCC. 9 therapeutic  regimen .  The  detection  of 
Conclusion soluble K19 fragments in the serum released 
Cyfra 21-1 have the potential to be  by carcinoma cells by the Cyfra 21-1 assay 
valuable tools for diagnosis, prognosis, and  has  found  broad  clinical  application  as  a 
treatment  monitoring  of  different  cancers.  marker to monitor treatment and evaluate 
10 Their clinical utility has been demonstrated in  response to therapy .
lung and breast cancer and to some extent in  Cyfra 21-1 in diagnosis, prognosis and 
head  and  neck  cancers.  It  is  apparent  that  surveillance of cancers
these  markers  may  also  prove  useful  in 
11 Ilana Doweck et al (1995)  measured  predicting  the  risk  of  recurrence  and/or 
Cyfra 21-1 (cytokeratin fraction 21-1) in oral  involvement  of  regional  lymph  node 
squamous  cell  carcinoma  patients    and  metastasis in human oral cancers. However, 
found  Cyfra  21-1  levels  were  in  good  systematic  follow-up  studies  from  defined 
  correlation with the tumor stageexpressed by  sub-sites  and  using  antibodies  specific  to 
the tumor size and the lymphatic spread (N)  identified  CK  fragments  in  circulation  are 
  and were inversely correlated with histologic  necessary  to  evaluate  their  sensitivity  and 
grades. specificity before they can be used as non 
12  invasive markers for prognostication, follow- Kurokawa et al (1997) found 90% 
up of therapy, and detection of recurrence  accuracy for cyfra21-1 and concluded Cyfra 
and metastases in oral cancer. may be useful for the screening of patients 
with suspected oral squamous cell carcinoma.  371 Cyfra 21-1: An Overview
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